September 16, 2007

The Effect of Long-Term Treatment With Sulindac on the Progression of Diabetic Retinopathy*

By Hattori, Yukiko Hashizume, Kiyoshi; Nakajima, Kazuo; Nishimura, Yoshihiro; Et al

Key words: Diabetic retinopathy - Long-term treatment - Sulindac - Type 2 diabetes ABSTRACT

Objective: To evaluate the effects of long-term treatment with sulindac on the progression of diabetic retinopathy (DR).

Research design and methods: 40 Japanese patients with type 2 diabetes were enrolled in a randomized, single-blind controlled trial in which the effects of sulindac (200 mg/day, 100 mg twice a day; n = 16 patients) on the progression of DR were compared to controls (24 patients) for 3 years. All patients were comparable in their age, gender, duration of disease, body mass index, dipstick proteinuria, insulin therapy, glycemic control, and clinical stages of DR. Outcome was determined by comparing parameters of retinopathy in fundus photographs that were taken at time 0 to those taken 1 , 2, and 3 years after the initiation of treatment.

Results: Patients in the sulindac group did not develop DR during the course of treatment nor was there progression of pathology in those who began the study with mild non-proliferative DR (NPDR). On the other hand, six patients progressed to mild NPDR in the control group - three at year 1 and three at year 3 - and an additional patient progressed to severe NPDR from mild NPDR by year 1 and to proliferative DR by year 2. The findings at year 3 in the sulindac group were significantly (p

Conclusions: Long-term treatment with sulindac was clinically effective in decreasing the progression of mild DR in type 2 diabetic patients in this pilot study.


Diabetic retinopathy (DR) is one of the chronic complications of type 2 diabetes. The pathogenesis is complex, with risk factors including hyperglycemia and hypertension1. Glycemie control is the most important factor to prevent occurrence or progression of DR1. It is also reported that tight blood pressure control reduces the risk of DR23. The renin-angiotensin system has been implicated in DR, and angiotensin-converting enzyme inhibitors were shown to decrease the progression of mild DR4. However, to date there have been few reports of other preventive drug treatments for DR, although photocoagulation and vitrectomy are well-established surgical treatments for advanced DR.

Sulindac, which is used clinically for the treatment of pain and arthritis5, and is structurally related to indomethacin, is a prodrug which is metabolized to sulfide and sulfone derivatives in the liver and by colonic bacteria6. The non-steroidal anti- inflammatory drugs (NSAIDs), such as sulindac and acetylsalicylic acid, have aldose reductase (AR) inhibitory activity7. The activity of sulindac is greater than that of other classes of anti- inflammatory agents8,9. Sulindac sulfide is the drug's most active metabolite, which blocks prostaglandin synthesis by non-selective inhibition of cyclooxygenase (COX)-1 and -2. Sulindac also inhibits the production of inflammatory cytokines by blocking the nuclear factor-kappaB (NF-kappaB) pathway10. Sulindac was reported to prevent retinal capillary basement membrane thickening in early DR in cats" and dogs12, but was ineffective in preventing disease progression over a short, 6-month clinical course13.

We proposed that long-term treatment with sulindac would be effective in blocking the progression of DR when begun at an earlier stage, since AR is thought to be principally involved in the development of early stage complications"4. In the present pilot study, we tested the hypothesis that longer-term treatment with sulindac might be more effective in decreasing the progression of early DR.

Patients and methods

Study population

The study was carried out between October 1997 and October 2000. We intended to set up a larger study based on this pilot study. Forty middle-aged Japanese patients with type 2 diabetes, all seen at Asama General Hospital, were enrolled in this randomized, single blind, controlled trial. All patients had been diabetic for more than 5 years and exhibited poor glycemie control (glycosylated hemoglobin [HbA^sub 1c^] > 8.0%); they were all normotensive (

Study design

The patients were then randomized with stratification to the following two groups: (1) a sulindac group (n = 16) in which patients took 100 mg of sulindac twice a day; and (2) a control group (n = 24) in which patients took no additional medications. The patients remained on their medications for 3 years. Safety was assessed by the recording of treatment-emergent adverse events, and by systemic physical examinations. Laboratory tests included a hematologic panel and measurements of liver and kidney function. HbA^sub 1c^ values were determined at monthly intervals. In addition, patients were examined by seven-field stereoscopic retinal photography at baseline and at yearly intervals; all of these photographs were evaluated by the same ophthalmologist who was unaware of the study design. Patients were classified as exhibiting no apparent retinopathy, mild non-proliferative DR (NPDR), moderate NPDR, severe NPDR, or proliferative DR (PDR), as per the International Clinical Diabetic Retinopathy Disease Severity Scale. During the course of the study, patients were considered to have reached an endpoint if they were diagnosed with PDR or if they exhibited a dipstick proteinuria of >/= 1 +, which was taken as a sign of nephropathy.

Statistical analysis

Continuous variables are presented as mean +- SD. The significance of the differences between baseline patients' data in the two groups was estimated by Student's t-test or the Mann- Whitney U test. Parameters of retinopathy were compared using the Mann-Whitney U test. The significance value was set at 0.05.


Informed consent was obtained from all patients prior to initiation of the study. The study was conducted in accordance with the principles of the Declaration of Helsinki, and was approved by the Institutional Review Board of Asama General Hospital.


Study participants

The baseline characteristics of the randomized patients are presented in Table 1. Patients in the two groups were comparable in age, duration of disease, body mass index, dipstick proteinuria, and clinical stages of DR. They had also had similar insulin treatment regimens and levels of glycemie control; the gender frequencies in both groups were also comparable. At the initiation of the trial, patients either exhibited no apparent retinopathy or mild NPDR; there were no significant differences in retinal pathology between groups at baseline (Table 2).


None of the patients in the sulindac group exhibited any progression of disease during the course of the study. On the other hand, three control patients developed mild NPDR after 1 year which persisted through year 3, while another patient's mild NPDR progressed to severe NPDR after 1 year. This severe NPDR of the latter patient progressed to PDR in year 2, after which she dropped out of the study and received photocoagulation therapy. Finally, three additional control patients developed mild NPDR at year 3 (Table 3). This resulted in a statistically significant decrease in the progression of clinically apparent DR at year 3 (p = 0.0284), but no differences at year 1 and year 2 (both p = 0.0895).

Table 1. Patients' baseline data

Table 2. Baseline ophthalmohgic evaluation


Neither blood pressure nor HbAlc levels changed in any of the patient groups, nor did they suffer any adverse effects of treatment. One patient did drop out of the study because she had reached a defined end point.


The polyol pathway, the formation of advanced glycation end products (AGEs), oxidative stress, and the activation of protein kinase C (PKC) have all been implicated in the development of diabetic complications' and interact with one another15,16. AR is the first and rate-limiting enzyme in the polyol pathway. In its native form, AR has a low affinity for glucose but sorbitol production is enhanced in a hyperglycemic environment14.

Table 3. Effects of treatment on the progression of retinopathy

Recent findings have suggested that DR may represent a chronic inflammatory disease. Activation of the polyol pathway leads to activation of PKC which further increases cytosolic phospholipase A^sub 2^ activity. Activation of this enzyme increases the production of two inhibitors of Na^sup +^-K^sup +^ ATPase- arachidonate and prostaglandin E^sub 2^17. The expression of retinal intercellular adhesion molecule-1 (ICAM-1) and the leukocyte integrin CD18 is up-regulated in DR; proinflammatory cytokines such as vascular endothelial growth factor (VEGF) are known to drive the up-regulation of ICAM-1, most likely via nitric oxide- and NF- kappaB-dependent pathways18. The production of tumor necrosis factor- alpha (TNF-alpha), a vasoactive cytokine, is also elevated in DR19.

It was recently shown that COX, especially COX-2, interacts with VEGF20. COX-1 is a constitutively expressed isoform that is found in most tissues. In contrast, COX-2 is not normally expressed but is induced by pro-inflammatory and mitogenic stimuli such as VEGF, TNF- alpha, and interleukins-1 a and -1beta. COX-2 is also thought to interact with NF-kappaB, interleukin 6, and cyclic adenosine monophosphatase21. Numerous reports have suggested that aldose reductase inhibitors (ARIs) can prevent the occurrence and progression of experimental DR11,12,22. In contrast to the success seen in animal models, ARIs have not been shown to provide appreciable clinical benefit for the treatment of human DR23,24. The diabetic animal models only show the early signs of DR14, and are generally carried out in severely hyperglycemic conditions to induce DR at higher rates and more rapidly14. In contrast, the diabetic patients in the human trials are usually well- to moderately- controlled.

We planned our pilot study in the light of the above considerations. At baseline, the patients in our study all had no apparent retinopathy or mild NPDR. Patients in the sulindac group took the drug for 3 years. Our data showed that 3-years' treatment with sulindac resulted in a statistically significant decrease in the progression of DR in type 2 diabetic patients. On the other hand, we were not able to show that sulindac significantly suppresses the progression of DR because of the small size of the study.

While sulindac prevented retinal capillary basement membrane thickening in diabetic dogs, it had no effect on the activity of the polyol pathway, the accumulation of AGEs, or oxidative stress12. Thus, the suppression of inflammatory cytokines and COX by sulindac might also be important. It is likely that the other effects of sulindac also contribute to its ability to prevent DR. Our study has unavoidable limitations because of its small size, and we therefore now plan to conduct investigations, including a comparison of the effects of sulindac with specific ARIs or other NSAIDs on DR, and to explore the mechanisms underlying sulindac 's effect. To this end, a much larger study population will be required.


We found that treatment with sulindac for 3 years was clinically effective in decreasing the progression of early DR in type 2 diabetic patients in this pilot study. Larger scale clinical trials will be required to confirm these findings. In order to define the action mechanisms of sulindac, further studies are needed. But the beneficial effect of sulindac is important to decrease the progression of DR.


Declaration of interest: No conflict of interest was declared.


1. Fong DS, Aiello LP, Ferris FL 3rd, et al. Diabetic retinopathy. Diabetes Care 2004;27:2540-53

2. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. BMJ 1998;317:703-13

3. Matthews DR, Stratton IM, Aldington SJ, et al. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol 2004;122:1631-40

4. Chaturvedi N, Sjolie AK, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998;351:28-31

5. Tugwell P, Ludwin D, Gent M, et al. Interaction between cyclosporin A and nonsteroidal antiinflammatory drugs. J Rheumatol 1997;24:1122-5

6. Duggan DE, Hooke KF, Risley EA, et al. Identification of the biologically active form of sulindac. J Pharmacol Exp Ther 1977;201:8-13

7. Kador PF, Kinoshita JH, Sharpless NE. The aldose reductase inhibitor site. Metabolism 1986;35:109-13

8. Brogden RN, Heel RC, Speight TM, et al. Sulindac: a review of its pharmacological properties and therapeutic efficacy in rheumatic disease. Drugs 1978;16:97-114

9. Sharma YR Cotlier E. Inhibition of lens and cataract aldose reductase by protein-bound anti-rheumatic drugs: salicylate, indomethacin, oxyphenbutazone, sulindac. Exp Eye Res 1982;35:21-7

10. Yamamoto Y, Yin M-J, Lin K-M, et al. Sulindac inhibits activation of the NF-kappaB pathway. J Biol Chem 1999;274: 27307-14

11. Mansour SZ, Hatchell DL, Chandler D, et al. Reduction of basement membrane thickening in diabetic cat retina by sulindac. Invest Ophthalmol Vis Sci 1990;31:457-63

12. Gardiner TA, Anderson HR, Degenhardt T, et al. Prevention of retinal capillary basement membrane thickening in diabetic dogs by a non-steroidal anti-inflammatory drug. Diabetologia 2003;46:1269-75

13. Cunha-Vaz JG, Mota CC, Leite EC, et al. Effect of sulindac on the permeability of the blood-retinal barrier in early diabetic retinopathy. Arch Ophthalmol 1985;103:1307-11

14. Chung SS, Chung SK. Aldose reductase in diabetic microvascular complications. Curr Drug Targets 2005;6:475-86

15. Hamada Y, Araki N, Horiuchi S, et al. Role of polyol pathway in nonenzymatic glycation. Neprol Dial Transplant 1996,11: 95-8

16. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 1992;258:607-14

17. Xia P, Kramer RM, King GL. Identification of the mechanism for the inhibition of Na^sup +^, K^sup (+)^-adenosine triphosphatase by hyperglycemia involving activation of protein kinase C and cytosolic phospholipase A2. J Clin Invest 1995;96:733-40

18. Joussen AM, Poulaki V, Le ML, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004;18:1450-2

19. Bloomgarden ZT. Diabetic retinopathy and neuropathy. Diabetes Care 2005;28:963-70

20. Ayalasomayajula SP, Kompella UB. Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin- induced diabetic rat model. Eur J Pharmacol 2003;458: 283-9

21. Wadleigh DJ, Reddy ST, Kopp E, et al. Transcriptional activation of the cyclooxygenase-2 gene in endotoxin-treated RAW 264.7 macrophages. J Biol Chem 2000;275: 6259-66

22. Kato N, Yashima S, Suzuki T, et al. Long-term treatment with fidarestat suppresses the development of diabetic retinopathy in STZ- induced diabetic rats. J Diabetes Complications 2003;17:374-9

23. Sorbinil Retinopathy Trial Research Group. A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Arch Ophthalmol 1990;108:1234-44

24. Tromp A, Hooymans JM, Barendsen BC, et al. The effects of an aldose reductase inhibitor on the progression of diabetic retinopathy. Doc Ophthalmol 1991;78:153-9

CrossRef links are available in the online published version of this paper:

Paper CMRO-3921_3, Accepted for publication: 11 June 2007

Published Online: 06 July 2007


Yukiko Hattori(a), Kiyoshi Hashizume(b), Kazuo Nakajima(a), Yoshihiro Nishimura(a), Motoji Naka(a) and Kazuto Miyanaga(c)

a Department of Internal Medicine, Asama General Hospital, Saku, Japan

b Department of Aging Medicine and Geriatrics, Institute of Aging and Adaptation, Shinshu University Graduate School, Matsumoto, Japan

c Department of Ophthalmology, Tatsuno General Hospital, Tatsuno, Japan

Address for correspondence: Yukiko Hattori, Department of Molecular Oncology, Division of Molecular and Cellular Biology Institute on Aging and Adaptation, Shinshu University Graduate School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan. Tel.: +81 263 37 2723; Fax: +81 263 37 2724; [email protected]

Copyright Librapharm Aug 2007

(c) 2007 Current Medical Research and Opinion. Provided by ProQuest Information and Learning. All rights Reserved.